Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 28, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,350,000 Ordinary shares
- Purchase Price: 1,284.18 pence per share
- Treasury Shares Held: 373,337,158 (representing 6.61% of total voting rights)
- Shares in Issue: 5,649,001,897 (excluding Treasury shares)
Material Changes
The primary material change reported is the reduction of outstanding shares through the acquisition of 1,350,000 shares for Treasury. Consequently, the total number of shares held in Treasury increased to 373,337,158. The filing does not provide comparative data for prior periods regarding financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of specific risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,649,001,897) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (373,337,158) and its impact on total voting rights (6.61%).
- Review the Annual General Meeting minutes from May 23, 2007, to understand the full scope of the share repurchase authority.